Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Pediatr Urol ; 19(5): 582.e1-582.e5, 2023 10.
Artículo en Inglés | MEDLINE | ID: mdl-37353360

RESUMEN

INTRODUCTION: Double-diaper technique with an open-drainage catheter is a common practice after hypospadias repair. However, double-diapering may increase the burden of postoperative care and has not been compared to single-diapering with an open-drainage catheter. OBJECTIVES: This study investigates whether the single-diaper technique is associated with inferior surgical outcomes compared to the double-diaper technique. MATERIALS AND METHODS: A single surgeon database was retrospectively reviewed for patients who underwent hypospadias repair between 2013 and 2021. Patients who were lost to follow-up and those in whom the type of diaper care (single- or double-diaper) was not documented were excluded. Patients in the single-diaper technique received the same type of dressing and discharge instructions, as those in the double-diaper group, except for leaving the catheter freely draining into a single-diaper. Short-term complications including surgical site infection (SSI), urinary tract infection (UTI) and wound dehiscence, were the primary outcome; whereas the long-term urethroplasty complications (urethrocutaneous fistula and meatal stenosis) were secondary outcomes. Outcomes were analyzed according to the type of diaper care. RESULTS: Among 323 patients reviewed, 219 patients met the inclusion criteria (72 patients in the double-diaper and 147 in the single-diaper group). Both study groups were similar regarding patient demographics, hypospadias characteristics and surgical technique. Looking at the primary outcomes, there was no statistically significant difference in SSI, UTI or wound dehiscence. For the secondary outcomes, the incidence of meatal stenosis (8.3 vs. 1.4%, p = 0.044), and fistula formation (15.3% vs 5.4%, p = 0.037) was significantly higher in the double-diaper than the single-diaper group, respectively (Table 2). CONCLUSION: Single-diaper technique following hypospadias repair is not associated with increased risk of complications compared to double-diaper technique.


Asunto(s)
Fístula , Hipospadias , Estrechez Uretral , Masculino , Humanos , Lactante , Hipospadias/cirugía , Hipospadias/etiología , Estudios Retrospectivos , Constricción Patológica/etiología , Uretra/cirugía , Infección de la Herida Quirúrgica , Estrechez Uretral/cirugía , Fístula/etiología , Fístula/cirugía , Resultado del Tratamiento , Complicaciones Posoperatorias/cirugía , Procedimientos Quirúrgicos Urológicos Masculinos/efectos adversos , Procedimientos Quirúrgicos Urológicos Masculinos/métodos
2.
Urol Case Rep ; 45: 102212, 2022 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-36117734

RESUMEN

We present a case of extensive Condyloma acuminata lesions involving significant area of the penile and genital skin. He underwent a complete excision of the lesions. Reconstruction of the penile skin was performed using full-thickness skin graft. The patient recovered well with no graft contracture or disfigurement.

3.
Cureus ; 14(1): e21673, 2022 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-35237473

RESUMEN

Primary hyperoxaluria type 1 (PH1) is a rare genetic disease that results in oxalate overproduction leading to nephrolithiasis (NL), nephrocalcinosis (NC), kidney failure, and systemic oxalosis. Infantile PH1 is its most severe form, and it may require intensive hemodialysis followed by a liver-kidney transplant. Lumasiran is an RNA interference (RNAi) therapeutic agent that reduces hepatic oxalate production, which has been recently approved for the treatment of PH1. In this report, we present a case of twin males with infantile PH1 and bilateral NL and NC who were treated with lumasiran at 12 months of age. Their symptoms abated after therapy was started without disease progression. To the best of our knowledge, this is the first report of PH1 occurring in twins and the first report on using lumasiran to treat infantile PH1 outside of a clinical trial. Lumasiran appears to be a successful therapeutic option for infantile PH1.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA